Board approves allotment of shares to promoter Shankar Varadharajan following warrant conversion under SEBI Regulation 30 disclosure
Institute signs four MoUs, launches two products and marks 75 years with renewed focus on lab-to-market commercialisation
Company leadership is framing the move as transformational.
DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
Capital infusion to accelerate Earendil’s R&D platform
The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%
The company has shown remarkable growth, posting a three-year CAGR of around 75% with an ARR of roughly Rs 100 crore and impressive gross margins
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The unveiling marks Time Medical India’s entry into next-generation helium-free MRI technology
Subscribe To Our Newsletter & Stay Updated
